Fig. 3

HIF-1α/GLI-1/EZH2 are the major TFs for EZH2-integrin α11 axis overexpression

(A) Cancer stem cell transcription factor activating profiling plate array. The bar graph represents mean SEM of three independent experiments. (B) Comparison of TF expression levels between the EZH2- or SUZ12-OV and drug-resistant cells. Fold change values are derived from three independent experiments. (C) The effects of various TF inhibitors on the expression of EZH2, SUZ12, Integrin α11 in TAMR or ADR cells. MTRM A, GLDM, and Int represent mithramycin A, geldanamycin, and integrin, respectively. (D) Comparison of integrin α11 expression levels by silencing TFs, HIF-1α, GLI-1, and EZH2 in TAMR or ADR cells. *p < 0.05 compared to siNT-transfected group. (E, F) ChIP and qPCR validation demonstrating HIF-1α, GLI-1, or EZH2 binding to ITGA11 (E) and EZH2 (F). Negative control (IgG) and positive control (RNA polymerase II) were used